You are now viewing our public site. Back to Dashboard

Duchenne Muscular Dystrophy Part 1: What We Know Now

presented by Claudia Senesac, PT, PhD, PCS

Accrediting Body:

Target Audience:

Disclosure Statement:

Satisfactory completion requirements: All disciplines must complete learning assessments to be awarded credit, no minimum score required unless otherwise specified within the course.

MedBridge is committed to accessibility for all of our subscribers. If you are in need of a disability-related accommodation, please contact [email protected]. We will process requests for reasonable accommodation and will provide reasonable accommodations where appropriate, in a prompt and efficient manner.

Accreditation Check:

Duchenne Muscular Dystrophy (DMD) is the most common childhood muscular dystrophy. Much of what we have known about this disease has been based on years of clinical observation, muscle biopsy, and other limited testing. Longitudinal studies and clinical trials are shaping our "new understanding" of this disease. The courses related to DMD will span pathophysiology, research, the development of therapy recommendations, and quality of life issues. Therapy recommendations are based on predictive models of biomarkers and function, helping therapists and families plan for the future. Therapists play a critical role in caring for boys and young men with this disease.

Meet Your Instructor

Claudia Senesac, PT, PhD, PCS

Claudia Senesac is a clinical associate professor at University of Florida in the Doctor of Physical Therapy department. Her teaching responsibilities include functional anatomy dissection and pediatrics in physical therapy. She has over 37 years of pediatric clinical experience. She has been the owner and administrator of a pediatric physical therapy private practice since 1984…

Read full bio

Chapters & Learning Objectives

Download Learning Objectives Download Learning Objectives

Enter your information to unlock the learning objectives.

Thank you!

Download the learning objectives for Duchenne Muscular Dystrophy Part 1: What We Know Now.

Download Learning Objectives

1. What We Know Now

The chapter will provide foundational background information to enhance the participants' understanding of DMD. Signs and symptoms of this disease will be detailed and the process of differential diagnosis reviewed. The most common medications and supplements will be covered.

2. Identified Biomarkers

Identified biomarkers have helped to further our understanding of this disease and monitor disease progression. Selected biomarkers have been developed and are emerging as outcome measures in research.

3. Research and Understanding DMD

Longitudinal research studies shed light on our current understanding of DMD. Correlations of multiple outcomes help make predictions for function. Predictions of function allow for planning for the future.

Sign up to get free evidence-based articles, exclusive discounts, and insights from industry-leaders.

Join our newsletter to get the latest updates delivered straight to your inbox.

MedBridge blog posts and emails

Request a Demo

For groups of 5 or more, request a demo to learn about our solution and pricing for your organization. For other questions or support, visit our contact page.

Contact Sales

Contact sales to learn about our solution and pricing for your organization. For other questions or support, visit our contact page.